Adicet Bio doses first patient in Phase 1 trial of ADI-270 for advanced clear cell renal cell carcinoma

Adicet Bio, Inc.

First patient dosed in Phase 1 trial of ADI-270, an allogeneic gamma delta 1 CAR T cell therapy, for metastatic/advanced ccRCC.
Phase 1 trial is multicenter, open-label, monotherapy; starting dose 3E8 CAR+ cells with option for second dose.
Company expects to report preliminary Phase 1 clinical data in the first half of 2025.
Preclinical data showed ADI-270 demonstrated tumor infiltration, resistance to immunosuppressive TME, and potent CAR/innate activity.
ccRCC is the most common kidney cancer; patients with advanced disease have limited treatment options and high unmet need.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.